氟伐他汀与曲美他嗪联合治疗不稳定型心绞痛疗效观察被引量：3

下载PDF

导出

摘要目的探讨氟伐他汀与曲美他嗪联合治疗不稳定型心绞痛的临床疗效。方法将120例不稳定型心绞痛随机分成2组,对照组应用硝酸酯类β-受体阻滞剂常规治疗,治疗组在常规治疗基础上口服氟伐他汀40 mg,1次/d;曲美他嗪20mg,3次/d,观察治疗后疗效及心血管事件发生情况。结果治疗3月后,治疗组的总有效率(93.9%)明显高于对照组(68.8%),两组相比差异有显著性意义(P<0.01)。严重心血管事件发生率明显低于对照组(P<0.01)。结论氟伐他汀与曲美他嗪联合治疗不稳定型心绞痛。能显著改善心绞痛的临床症状并减少心血管不良事件的发生。

作者葛琳

机构地区济宁樱花医院

出处《济宁医学院学报》 2008年第3期219-220,共2页 Journal of Jining Medical University

关键词心绞痛不稳定型氟伐他汀曲美他嗪疗效

分类号 R541.4 [医药卫生—心血管疾病] R972.6 [医药卫生—药品]

引文网络
相关文献

参考文献12

1不稳定性心绞痛诊断和治疗建议[J].中华心血管病杂志,2000,28(6):409-412. 被引量：2696
2梁春,吴宗贵.他汀类药物调脂治疗的昨天、今天和明天[J].上海医学,2005,28(4):270-273. 被引量：3
3Voger RA, Corretti MC, Plotnick GN, et al. Changes in flow mediated braehial artery vasoaetivity with lowering of desirable cholesterol levels in healthy middleaged men. Am Cardiol, 1996,77:37
4Lewis S J, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction:The Cholesterol and Recurrent Events(CARE) trial. J Am Coll Cardiol, 1998,32:40
5Baetta R, Donetti E, Comparato C, et al. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. J Pharmacol Res, 1997,36:2115
6Laufs U, La - Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998,97 : 1129
7Chen L, Haught WH, Yang B, et al. preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanism of antiatherosclerotic effects of vitamin E,lovastatin and amlodipine. J Am Coll Cardiol,1997 ,30 :569
8杜习智,王豫辉,董根山,王爱风,孟宪丽,李瑞敏,王留义.阿托伐他汀对急性冠状动脉综合征早期血脂和炎症因子的影响[J].陕西医学杂志,2006,35(12):1600-1602. 被引量：6
9杭娟,王志坚,蒋宝琦.辛伐他汀干预治疗对不稳定心绞痛患者血清高敏C-反应蛋白的影响[J].陕西医学杂志,2006,35(4):426-428. 被引量：4
10殷忠,刘丽文,李兰荪,钱蕴秋,刘海涛,谢学建,王海昌.长期应用阿托伐他汀对冠心病患者颈动脉系统血流动力学的影响[J].陕西医学杂志,2007,36(4):418-421. 被引量：4

二级参考文献34

1刘有军,刁越,高松.血流动力学与动脉粥样硬化(一)[J].北京生物医学工程,2004,23(4):293-295. 被引量：13
2陈莹,刘复强,常志文.冠心病患者外周血MCP-1、sICAM-1、CD11b水平的变化[J].陕西医学杂志,2005,34(8):931-934. 被引量：5
3Spencer FA, Allegrone J, Goldberg RJ,et al. Association of statin therapy with outcomes of acute coronary syndromes:the GRACE study. Ann Intern Med. 2004,140:857-866.
4Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 2001,285:1711-1718.
5Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med,2004, 350:1495-1504.
6Blazing MA, De Lemos JA, Dyke CK,et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J, 2001, 142:211-217.
7Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). JAMA, 2001,285:2486-2497.
8Campeau L, Hunninghake DB, Knatterud GL, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation, 1999,99:3241-3247.
9McCormick LS, Black DM, Waters D, et al. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). Am J Cardiol,1997,80:1130-1133.
10Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. Circulation,2004,110:227-239.